thyroid nodules and thyroid cancer

in review 5 min read Updated 2026-11-19
thyroid nodules and thyroid cancer

Always start with TSH + neck ultrasound. Low TSH → radionuclide scan (hyperfunctioning “hot” nodules are almost never malignant — do not FNA). Normal/high TSH → risk-stratify by ACR TI-RADS to decide FNA (TR3 ≥2.5 cm, TR4 ≥1.5 cm, TR5 ≥1.0 cm). In differentiated thyroid cancer (ATA 2025), de-escalate: lobectomy is sufficient for many low-risk tumours, and long-term TSH suppression is no longer suggested for low/intermediate-risk patients with an excellent response.

do not miss

Anaplastic thyroid cancer (rapidly enlarging, rock-hard neck mass with stridor/dysphagia → urgent airway + core biopsy + rapid BRAF V600E). Before any surgery for medullary thyroid cancer, exclude phaeochromocytoma (metanephrines) to prevent intraoperative hypertensive crisis.


initial nodule workup — TSH first

flowchart TD
  A["palpable or incidental thyroid nodule"] --> B["serum TSH + diagnostic thyroid/neck US"]
  B --> C{"TSH suppressed?"}
  C -- yes --> D["¹²³I or ⁹⁹mTc thyroid scan"]
  D --> E{"hyperfunctioning\n(hot) nodule?"}
  E -- yes --> F["NO FNA — treat hyperthyroidism\n(RAI, surgery, or ATD)"]
  E -- no (cold / isofunctioning) --> G["ACR TI-RADS US stratification"]
  C -- no (normal / high) --> G
  G --> H{"meets TI-RADS\nsize threshold?"}
  H -- yes --> I["US-guided FNA → Bethesda I–VI"]
  H -- no --> J["US surveillance or no follow-up"]
  • Do not measure routine serum thyroglobulin for nodule diagnosis (non-specific; used only for post-treatment DTC surveillance). Measure serum calcitonin only if suspicious for medullary thyroid cancer (family history of MTC/MEN2, suggestive cytology) — not routinely in North America.
  • High-risk clinical features (lower threshold for FNA/workup): childhood head/neck radiation, family history of thyroid cancer / MEN2 / Cowden / FAP, rapid growth, hoarseness/vocal cord palsy, fixed firm nodule, cervical lymphadenopathy, or FDG-PET–avid thyroid incidentaloma (~30–40% malignancy risk).

ACR TI-RADS ultrasound stratification

Points are summed across 5 features — highest-suspicion features include solid composition (2), markedly hypoechoic (3), taller-than-wide shape (3), lobulated/irregular margins (2) or extrathyroidal extension (3), and punctate echogenic foci / microcalcifications (3).

ACR TI-RADSpointssuspicion (cancer risk)FNA thresholdUS follow-up threshold
TR10benign (≤2%)no FNAnone
TR22not suspicious (≤2%)no FNAnone
TR33mildly suspicious (~5%)≥2.5 cm≥1.5 cm (1, 3, 5 y)
TR44–6moderately suspicious (5–20%)≥1.5 cm≥1.0 cm (1, 2, 3, 5 y)
TR5≥7highly suspicious (≥20%)≥1.0 cm≥0.5 cm (annual × 5 y)
  • Purely cystic and spongiform nodules (TR1) do not need FNA regardless of size (drain only if symptomatic).
  • ATA 2015 vs ACR TI-RADS: ATA 2015 uses slightly lower cut-offs for intermediate/low suspicion (1.0 / 1.5 cm); ACR TI-RADS (2.5 / 1.5 / 1.0 cm) is standard in Canadian radiology reporting and cuts unnecessary biopsies.

bethesda cytology categories

categoryrisk of malignancynext step
I — non-diagnostic5–10%repeat US-guided FNA
II — benign<3%no intervention; US follow-up only if high-suspicion US or growth
III — AUS / FLUS~10–30%repeat FNA, molecular testing, or diagnostic lobectomy
IV — follicular neoplasm~25–40%molecular testing or diagnostic lobectomy (FNA cannot distinguish adenoma from carcinoma)
V — suspicious for malignancy~50–75%surgery (lobectomy or total thyroidectomy)
VI — malignant>97%surgery (or active surveillance for selected T1a papillary microcarcinoma <1 cm)

differentiated thyroid cancer (ATA 2025)

DTC (~90% papillary, ~10% follicular/oncocytic) has excellent prognosis; ATA 2025 emphasises de-escalation to avoid overtreatment.

  • Initial therapy:
    • Active surveillance: option for selected intrathyroidal papillary microcarcinomas (cT1aN0M0, ≤1 cm).
    • Lobectomy: sufficient for many low-risk cT1–T2 N0 M0 DTCs (lower hypoparathyroidism and RLN injury than total thyroidectomy).
    • Total thyroidectomy ± selective RAI: high-risk or selected intermediate-risk disease (gross ETE, clinically positive nodes, distant metastases, aggressive histology). NIFTP is not considered thyroid cancer (lobectomy alone, no RAI, no TSH suppression).
  • Dynamic response-to-therapy & TSH targets (ATA 2025 vs ATA 2015):
    • Excellent response (low/intermediate risk, undetectable Tg / negative neck US): TSH within the normal reference range after both total thyroidectomy and lobectomy (ATA 2025 shifts away from the older ATA 2015 0.5–2.0 mU/L band to avoid unnecessary LT4 after lobectomy, atrial fibrillation, and osteoporosis).
    • Indeterminate response: TSH within normal reference range per ATA 2025 (ATA 2015 suggested mild suppression 0.1–0.5 mU/L).
    • Biochemical or structural incomplete response: TSH below the normal reference range per ATA 2025 (individualised for progression vs cardiac/bone risk; ATA 2015 used 0.1–0.5 mU/L for biochemical incomplete and <0.1 mU/L for structural incomplete — no extra benefit below <0.03 mU/L).
  • Surveillance: serum thyroglobulin (Tg) + anti-Tg antibodies (anti-TgAb interferes with Tg assays — rising TgAb acts as a surrogate marker) + neck ultrasound.

medullary and anaplastic thyroid cancer

  • Medullary thyroid cancer (MTC) (parafollicular C-cells; ~25% hereditary via RET mutations):
    • Before any MTC surgery: measure calcitonin, CEA, serum calcium, and plasma/urine metanephrines (rule out phaeochromocytoma first so anaesthesia does not trigger hypertensive crisis!).
    • Offer germline RET testing to every patient with MTC → MEN2A / MEN2B.
    • RAI does not work (C-cells do not concentrate iodine) and TSH suppression is not indicated (replace to normal TSH).
  • Anaplastic thyroid cancer (ATC): rapidly enlarging, rock-hard neck mass with stridor/dysphagia in an older adult — airway emergency; immediate core biopsy + rapid BRAF V600E testing (dabrafenib + trametinib if BRAF-mutated) + multidisciplinary oncology/palliative care.

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+2 more sources

Suggest a correction thyroid nodules and thyroid cancer